Back to top

oncology-screening: Archive

Ahan Chakraborty

Recursion Pharmaceuticals Rises 6% in a Month: How to Play the Stock

RXRX gains 5.5% in a month on positive pipeline update; long-term hold advised given strong potential of its AI-driven drug discovery platform.

SNYPositive Net Change RHHBYNegative Net Change BAYRYPositive Net Change RXRXNegative Net Change

Zacks Equity Research

MRUS Stock Soars 30% in 3 Months After Phase II Cancer Study Success

Merus jumps 30% in three months after its cancer combo therapy showed significant efficacy in a phase II head and neck squamous cell carcinoma study.

MRKPositive Net Change BAYRYPositive Net Change MRUSNegative Net Change VRNAPositive Net Change

Ahan Chakraborty

Will RXRX's Shift in Pipeline Focus Help Restore Investor Faith?

Recursion Pharmaceuticals axes three drug programs after weak study data, but shifts focus to more promising candidates like REC-4881 to regain ground.

SDGRNegative Net Change RLAYNegative Net Change RXRXNegative Net Change